5-Fluor-1-(tetrahydro-2-furyl)uracil Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R23/24/25:Giftig beim Einatmen, Verschlucken und Berührung mit der Haut.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
Beschreibung
Tegafur is an orally bioavailable prodrug form of 5-fluorouracil (5-FU; ). It is converted to 5-FU
in vivo enzymatically or by cytochrome P450 oxidation. Tegafur inhibits proliferation of HT-29, BxPC-3, and Panc02 cells (IC
50s = 201, 172, and 179 μM, respectively). It also reduces tumor growth in an HT-27 colon carcinoma mouse xenograft model when administered at a dose of 50 mg/kg and in a 4-1ST gastric carcinoma mouse xenograft model when used in combination with uracil. Formulations containing tegafur, in combination with uracil, have been used in the treatment of cancer.
Chemische Eigenschaften
White Crystalline Powder
Verwenden
Isotope labelled Tegafur (T013900), used as an antineoplastic.
Sicherheitsprofil
Poison by ingestion.
Moderately toxic to humans by intravenous
route. Moderately toxic experimentally by
intraperitoneal, intravenous, and
subcutaneous routes. Experimental
teratogenic data. Human systemic effects:
nausea and vomiting. Experimental
reproductive effects. Questionable human
carcinogen producing gastrointestinal
tumors. Human mutation data reported.
Used as an anti-cancer agent. When heated
to decomposition it emits very toxic fumes
of Fand NOx.
5-Fluor-1-(tetrahydro-2-furyl)uracil Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
